Format

Send to

Choose Destination
Br J Cancer. 2017 Mar 28;116(7):893-902. doi: 10.1038/bjc.2017.26. Epub 2017 Feb 16.

PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype.

Author information

1
Martinos Center for Biomedical Imaging, Harvard Medical School, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129, USA.
2
Abdominal Imaging, Harvard Medical School, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
3
Department of Radiology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA.
4
Nuclear Medicine Unit, University of Rome 'La Sapienza', Viale del Policlinico 5, Rome 00161, Italy.
5
Breast Unit, Ospedale Moscati, Avellino 83010, Italy.
6
Department of Pathology, Ospedale Moscati, Avellino 83010, Italy.
7
Department of Biostatistics, Martinos Center for Biomedical Imaging, Harvard Medical School, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129, USA.
8
Department of Radiology, Gamma Cord, Benevento 82100, Italy.
9
Department of Radiology, University of Naples 'Federico II', Napoli 80131, Italy.
10
Breast Imaging, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
11
Diagnostic Imaging, SDN, Via Gianturco 113, Napoli 80131, Italy.
12
Diagnostic Imaging, University of Naples 'Parthenope', Napoli 80131, Italy.
13
Department of Radiology, Martinos Center for Biomedical Imaging, Harvard Medical School, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129, USA.
14
Precision Medicine and Radiology, Harvard Medical School, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129, USA.

Abstract

BACKGROUND:

Differences in genetics and receptor expression (phenotypes) of invasive ductal breast cancer (IDC) impact on prognosis and treatment response. Immunohistochemistry (IHC), the most used technique for IDC phenotyping, has some limitations including its invasiveness. We explored the possibility of contrast-enhanced positron emission tomography magnetic resonance (CE-FDG PET/MR) to discriminate IDC phenotypes.

METHODS:

21 IDC patients with IHC assessment of oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), and antigen Ki-67 (Ki67) underwent CE-FDG PET/MR. Magnetic resonance-perfusion biomarkers, apparent diffusion coefficient (ADC), and standard uptake value (SUV) were compared with IHC markers and phenotypes, using a Student's t-test and one-way ANOVA.

RESULTS:

ER/PR- tumours demonstrated higher Kepmean and SUVmax than ER or PR+ tumours. HER2- tumours displayed higher ADCmean, Kepmean, and SUVmax than HER2+tumours. Only ADCmean discriminated Ki67⩽14% tumours (lower ADCmean) from Ki67>14% tumours. PET/MR biomarkers correlated with IHC phenotype in 13 out of 21 patients (62%; P=0.001).

CONCLUSIONS:

Positron emission tomography magnetic resonance might non-invasively help discriminate IDC phenotypes, helping to optimise individual therapy options.

PMID:
28208155
PMCID:
PMC5379139
DOI:
10.1038/bjc.2017.26
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center